Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (June 25th Preview)
-
FDA expands Trodelvy label in front-line TNBC, intensifying the TROP2 ADC race
The FDA expanded Gilead Sciences’ Trodelvy to treat front-line triple-negative breast cancer (TNBC) regardless of PD-L1 status, giving the TROP2 antibody-drug conjugate a broader positioning in the growing first-line ADC market. The updated label allows Trodelvy either as monotherapy for patients ineligible for PD-1/L1 inhibitors or in combination with Merck’s Keytruda for PD-L1-positive tumors (combined positive score ≥10). The approval is supported by two Phase 3 trials. In Ascent-03, Trodelvy reduced the risk of progression or death by 38% versus chemotherapy in PD-(L)1 inhibitor-ineligible patients. In Ascent-04 (Keynote-D19), Trodelvy plus Keytruda improved progression-free survival by 35% versus Keytruda plus chemotherapy in PD-L1-positive disease. Regulatory action lands less than a month after a front-line TNBC approval for Daiichi Sankyo and AstraZeneca’s Datroway (trop2 ADC), setting up head-to-head commercial execution across overlapping biomarker segments. Gilead also highlighted clinical familiarity, citing Trodelvy’s use by more than 75,000 patients globally over six years. For the broader competitive landscape, analysts are watching whether subsequent trials can secure overall survival advantages and further narrow differences in patient selection across the PD-L1-positive and PD-L1-negative settings.
-
Merck KGaA makes record-scale move into life-science tools with Bio-Techne acquisition
Merck KGaA agreed to buy Bio-Techne for about $11.3 billion in cash, marking its largest deal since the Sigma-Aldrich acquisition in 2015. The offer values Bio-Techne at $73 per share and represents a 36% premium to the stock’s one-month average trading price, setting up a major consolidation of life-science tools, diagnostics technologies, and manufacturing capabilities. The transaction would add Bio-Techne’s core platforms and products, including recombinant proteins, antibodies, cytokines and immunoassays, plus ProteinSimple automated protein analysis systems and RNAscope multiplex RNA in situ hybridization. Merck KGaA also expects to acquire cell culture device manufacturer Wilson Wolf through Bio-Techne’s pending acquisition. Merck KGaA framed the deal as a strategic milestone under CEO Kai Beckmann, targeting broader service across discovery, translational research, testing, and commercial manufacturing. The company said it expects the deal to close by late 2026 or early 2027 and projects earnings-per-share pre-accretion by year three, alongside roughly €140 million in cost synergies. The scale and timing of the integration will be closely monitored by biotech and pharma customers that depend on reliable tools supply and lab workflows.
-
Ionis monetizes Alexander disease franchise with Recordati ex-U.S. licensing
Recordati licensed Ionis’ Alexander disease therapeutic candidate in a deal that shifts regulatory and commercial responsibilities to the Italian company. The arrangement supports Ionis’ strategy of regionalizing assets while capturing upfront value tied to commercialization rights outside the U.S. Separately, Ionis also secured $30 million upfront from Recordati for ex-U.S. rights to zilganersen, a near-approval rare disease antisense prospect. Together, the announcements underline Recordati’s continued appetite for rare-disease portfolios and Ionis’ focus on monetizing later-stage programs through licensing. For developers and investors, the key signal is how rare-disease companies are increasingly using regional rights and milestone-based structures to optimize balance sheets while accelerating global access paths.
-
Revolution’s second RAS blocker posts strong pancreatic cancer response signals and moves into Phase 3
Revolution Medicines reported high response activity for its second RAS inhibitor, zoldonrasib, in Phase 1/2 pancreatic ductal adenocarcinoma (PDAC) data focused on the KRAS G12D mutation. In RAS-G12D–mutated metastatic PDAC patients treated with zoldonrasib plus frontline mFOLFIRINOX, the overall response rate (ORR) reached 82%, compared with historical chemotherapy-only ORRs around 30% to 40%. The company also highlighted earlier ESMO GI plans that include additional combination readouts, including second-line data pairing zoldonrasib with daraxonrasib. Analysts cited the results as reinforcing Revolution’s opportunity to sustain leadership in PDAC amid expanding RAS-directed combinations. Revolution concurrently launched the Phase 3 RASolute 305 study testing zoldonrasib plus mFOLFIRINOX as a frontline regimen. If successful, the combination could expand options for patients with limited tolerability for more intensive regimens. The next major inflection for the program will come from the ongoing Phase 3 execution and how efficacy measures mature beyond early ORR signals.
-
Novartis pays Antares $105M to pursue undruggable oncology targets with small molecules
Novartis agreed to pay Antares Therapeutics $105 million upfront under a multi-year collaboration to discover small-molecule programs against cancer targets considered “undruggable.” The deal totals up to $1.9 billion across development, regulatory and commercial milestones, with tiered royalties on resulting products. Antares, a spinout from Scorpion Therapeutics, will apply its small-molecule discovery engine to uncover candidates directed to targets beyond conventional druggability assumptions. The partnership adds to Novartis’ oncology strategy as the Swiss company seeks to deepen pipeline capabilities beyond radiopharmaceuticals and build additional modalities. The collaboration is positioned as the biotech’s first new partnership since spinning out, and analysts will watch what target classes emerge from Antares’ discovery workflow and how quickly programs progress toward clinic. The immediate biotech implication is liquidity and runway support for early-stage discovery, while Novartis gains structured access to new chemistry opportunities tied to clear development gates.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.